Zanzalintinib
- Generic Name
- Zanzalintinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H25FN4O5
- CAS Number
- 2367004-54-2
- Unique Ingredient Identifier
- KC2JC2ZA04
- Associated Conditions
- -
- Associated Therapies
- -
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Anwaar Saeed
- Target Recruit Count
- 40
- Registration Number
- NCT06698250
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath